Disclosure of interest: nothing to disclose E-Posters - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P2516 - ESOC25-1205 ANALYSIS AFTER 2 YEARS OF EXPERIENCE WITH THE RUN-AIT PROTOCOL: ADVANCING TOWARDS IMPROVED MANAGEMENT OF TRANSIENT ISCHEMIC ATTACK Emilio Montero Ramrez 1 , Soledad Prez Snchez 1 , Reyes De Torres-Chacon 1 , Ana Barragn 1 , Antonio Bocero Garca 1 , lvaro Laviana Marn 1 , Teresa Busquier 2 , Isabel Morales Barroso 3 , Carmen Navarro Bustos 3 , Joan Montaner 1 Stroke Unit - Virgen Macarena University Hospital, Seville, Spain, 2 Radiology - Virgen Macarena University Hospital, Seville, Spain, 3 Emergency Department - Virgen Macarena University Hospital, Seville, Spain Background and Aims: 7.5%-17.4% of patients with transient ischemic attack(TIA) will experience a stroke within the next 3 months
Due to its well-characterised molecular profile and broad scientific interest, AOD-9604 remains a frequently referenced compound within peptide-focused research programmes
Stacking: Often combined with TB-500 for enhanced tissue repair and recovery synergy
Neuroscience 370:207217 Pillich RT, Scarsella G, Risuleo G (2005) Reduction of apoptosis through the mitochondrial pathway by the administration of acetyl-l-carnitine to mouse fibroblasts in culture
